BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 17489980)

  • 1. Gene silencing by DNA methylation in haematological malignancies.
    Boultwood J; Wainscoat JS
    Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
    Esteller M
    Oncogene; 2002 Aug; 21(35):5427-40. PubMed ID: 12154405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fundamental role of epigenetics in hematopoietic malignancies.
    Galm O; Herman JG; Baylin SB
    Blood Rev; 2006 Jan; 20(1):1-13. PubMed ID: 16426940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.
    Galm O; Wilop S; Lüders C; Jost E; Gehbauer G; Herman JG; Osieka R
    Ann Hematol; 2005 Dec; 84 Suppl 1():39-46. PubMed ID: 16231140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation and gene silencing in cancer: which is the guilty party?
    Clark SJ; Melki J
    Oncogene; 2002 Aug; 21(35):5380-7. PubMed ID: 12154400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis.
    Clark SJ
    Hum Mol Genet; 2007 Apr; 16 Spec No 1():R88-95. PubMed ID: 17613553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
    Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
    Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
    Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
    Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of gene promoters in hematological neoplasia.
    Chim CS; Liang R; Kwong YL
    Hematol Oncol; 2002 Dec; 20(4):167-76. PubMed ID: 12469326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of the MGMT gene in cancer.
    Soejima H; Zhao W; Mukai T
    Biochem Cell Biol; 2005 Aug; 83(4):429-37. PubMed ID: 16094446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic changes in solid and hematopoietic tumors.
    Toyota M; Issa JP
    Semin Oncol; 2005 Oct; 32(5):521-30. PubMed ID: 16210093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation.
    Jacinto FV; Ballestar E; Esteller M
    Oncogene; 2009 Nov; 28(47):4212-24. PubMed ID: 19734945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA hypermethylation: when tumour suppressor genes go silent.
    Garinis GA; Patrinos GP; Spanakis NE; Menounos PG
    Hum Genet; 2002 Aug; 111(2):115-27. PubMed ID: 12189484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of DNA hypermethylation in human neoplasia.
    Toyota M; Issa JP
    Electrophoresis; 2000 Jan; 21(2):329-33. PubMed ID: 10675010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant gene promoter methylation in plasma cell dyscrasias.
    Martin P; Garcia-Cosio M; Santon A; Bellas C
    Exp Mol Pathol; 2008 Jun; 84(3):256-61. PubMed ID: 18410922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies.
    Ying J; Gao Z; Li H; Srivastava G; Murray PG; Goh HK; Lim CY; Wang Y; Marafioti T; Mason DY; Ambinder RF; Chan AT; Tao Q
    Br J Haematol; 2007 Mar; 136(6):829-32. PubMed ID: 17341268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of bidirectional promoters by DNA methylation in tumorigenesis.
    Shu J; Jelinek J; Chang H; Shen L; Qin T; Chung W; Oki Y; Issa JP
    Cancer Res; 2006 May; 66(10):5077-84. PubMed ID: 16707430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.